PressAugust 3, 2023 COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
PressAugust 3, 2023 Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement
PressAugust 3, 2023 Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
PressAugust 3, 2023 Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
PressAugust 3, 2023 Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent
PressJuly 31, 2023 Psilocybin Potency, The Missing Link For Magic Mushroom Safety: Oakland’s Psychedelic Mushroom Church Announces Groundbreaking Information for Safe Use of Psilocybin Mushrooms
PressJuly 31, 2023 COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
PressJuly 28, 2023 Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
PressJuly 28, 2023 Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
PressJuly 28, 2023 Mind Cure Announces LNG Energy Group Credit Agreement in the Amount of U.S. $70 Million to Acquire Lewis Energy Colombia, Inc.
PressJuly 25, 2023 PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
PressJuly 25, 2023 First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
PressJuly 25, 2023 Filament Health Announces Upsizing and Closing of $2,500,000 Non-Brokered Private Placement Financing
PressJuly 21, 2023 PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale
PressJuly 20, 2023 Kernel’s Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects
PressJuly 20, 2023 Filament Health Corp. To List on Nasdaq Through Business Combination With Jupiter Acquisition Corporation
PressJuly 20, 2023 Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201
PressJuly 20, 2023 Mushrooms Inc. CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast
PressJuly 20, 2023 Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
PressJuly 20, 2023 PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney